BioInvent International Balance Sheet Health
Financial Health criteria checks 6/6
BioInvent International has a total shareholder equity of SEK1.0B and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK1.1B and SEK84.4M respectively.
Key information
0%
Debt to equity ratio
SEK 0
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 950.11m |
| Equity | SEK 1.00b |
| Total liabilities | SEK 84.38m |
| Total assets | SEK 1.09b |
Recent financial health updates
Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?
Aug 16
We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully
Apr 09Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth
Sep 01We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely
Sep 28Recent updates
Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?
Aug 16We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully
Apr 09Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth
Sep 01Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive
Jun 02Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week
Feb 25We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely
Sep 28Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook
Aug 31Financial Position Analysis
Short Term Liabilities: BINV's short term assets (SEK1.0B) exceed its short term liabilities (SEK76.1M).
Long Term Liabilities: BINV's short term assets (SEK1.0B) exceed its long term liabilities (SEK8.3M).
Debt to Equity History and Analysis
Debt Level: BINV is debt free.
Reducing Debt: BINV has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BINV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BINV has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 17.9% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/01 16:07 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioInvent International AB (publ) is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Morten Larsen | ABG Sundal Collier |
| Camilla Oxhamre | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |